Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

CANADA: Liquid Injectable Silicone Effective, Safe for Treating HIV Patients with Facial Lipoatrophy




 

Healio (05.31.2013) Aids Weekly Plus

Research in British Columbia, Canada, indicates that liquid injectable silicone administered properly has potential as a safe, effective, natural feeling treatment for patients with HIV-associated facial lipoatrophy (FLA). The researchers tested liquid injectable silicone because temporary filler treatments were not permanent and could result in high costs. Alastair Carruthers, FRCPC, clinical professor of the department of dermatology and skin science at the University of British Columbia, Vancouver, and colleagues studied 20 Caucasian patients (18 men) ages 34–58 with HIV-associated FLA. The patients received a maximum of 2 milliliters (mL) of 1,000-cSt highly purified medical-grade liquid injectable silicone at each session, with a maximum of six sessions. The researchers evaluated safety, efficacy, injection volumes, and patient satisfaction at 9, 12, and 18 months post-treatment. Eighteen patients received six sessions, one had five, and one had four sessions. After the fifth session, 15 patients had complete correction, 17 had complete correction after 9 months, and most patients maintained correction at 18-month follow-up. No patients reported persistent adverse events. The researchers concluded that that highly purified 1,000-cSt liquid injectable silicone, when administered by microdroplet technique of no more than 2mL per visit appeared to be promising and safe for treating HIV-associated FLA. They acknowledged that the study was limited by its small population size and was noncomparative and nonmasked. Carruthers stated that the small study justified a longer, larger study. The full report, “HIV-Associated Facial Lipoatrophy Treated with Injectable Silicone Oil: A Pilot Study,” was published online in the Journal of The American Academy of Dermatology (2013; doi:10.1016/j.jaad.2013.03.025).



 


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in June 3, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.